AstraZeneca applies for EU approval of its vaccine

The European Medicines Agency (EMA) introduced on Tuesday that British-Swedish producer AstraZeneca had utilized for authorization to distribute its vaccine within the EU.
The Amsterdam-based regulator stated that its evaluation of the vaccine would “proceed under an accelerated timeline.”
European Commission President Ursula von der Leyen referred to as the event “good news” in a tweet.
“Once the vaccine receives a positive scientific opinion, we will work full speed to authorize its use in Europe,” she wrote.
The EMA might subject an opinion on a conditional advertising and marketing authorization by January 29 at a gathering of its human medicines committee (CHMP).
It could be attainable to present authorization “provided that the data submitted on the quality, safety and efficacy of the vaccine are sufficiently robust and complete.”
If endorsed by the EMA and formally accepted by the European Commission, the AstraZeneca vaccine would turn into the third coronavirus inoculation out there within the bloc after BioNTech-Pfizer’s shot and Moderna’s jab.
Both the EU and the EMA have been beneath strain to speed up approval of latest vaccines, with the COVID-19 virus having claimed the lives of greater than 620,000 individuals throughout the continent.
The AstraZeneca vaccine has the main benefits of being each simpler to retailer than others and comparatively cheap, costing about 2.75 euros ($3.40) per dose. It does, nevertheless, seem to indicate decrease effectiveness in offering immunity.
An 82-year-old man turned the primary individual on the planet to obtain the Oxford-AstraZeneca jab because the UK rolled out the vaccine as a part of its inoculation program earlier this month.